Preferences help
enabled [disable] Abstract
Number of results
2020 | 31 | 138-145
Article title

Diagnostic and therapeutic challenges of Myasthenia Gravis: A report of 2 cases

Title variants
Languages of publication
Myasthenia gravis (MG) is an autoimmune disease that affects the neuromuscular junction and is characterized by muscle weakness. We present two clinical cases of patients with MG. The first case of the patient presents an uncharacteristic clinical picture in the form of dyspnoea with stridor. The second clinical case presents a severe form of MG, resistant to pharmacological cholinergic and immunosuppressive treatment, which resulted in a satisfactory improvement after eight plasmapheresis treatments and the conversion of pyridostigmine to the ambenonium.
Physical description
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, Lublin, Poland
  • [1] Evoli. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 30(5) (2017) 464-470
  • [2] M. Padilla Parrado, J.M. Morales Puebla, M.A. Díaz Sastre, et al. Respiratory stridency by larynx paralysis. Anusual beginning of miastenia. An Otorrinolaringol Ibero Am. 33(3) (2006) 307-315
  • [3] J.W. Fairley, M. Hughes. Acute stridor due to bilateral vocal fold paralysis as a presenting sign of myasthenia gravis. J Laryngol Otol. 106(8) (1992) 737-748
  • [4] Emeryk-Szajewska, M.H. Strugalska-Cynowska. Clinical picture of myasthenia gravis: diagnostic difficulties. Pol Przegl Neurol. 2(3) (2006) 145-149
  • [5] M.H. Strugalska-Cynowska. Myasthenia gravis and Lambert-Eaton myasthenic syndrome (clinical and immunological advances, signifity of autoantibodies for diagnosis and treatment). Pol Przegl Neurol. 15(1) (2019) 75-76
  • [6] W. Hoch, J. McConville, S. Helms, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylocholine receptor antibodies. Natur Medicine 7 (2001) 365-368
  • [7] H. Murai. Myasthenia gravis: past, present and future. Rinsho Shinkeigaku 54(12) (2014) 947-949
  • [8] Węgrzyn, J. Andres, D. Tomasik. Myasthenic crisis. Case report. Anestezjol Intensyw Terap. 3 (2002) 194-196
  • [9] Z. Rybicki. Intensywna terapia dorosłych. Novus Orbis. 1994, Gdańsk, Poland.
  • [10] N.E. Gilhus. Myasthenia Gravis. N Engl J Med. 375(26) (2016) 2570-2581
  • [11] K. Rejdak, S. Szklener, A. Korchut, et al. Cladribine in Myasthenia Gravis: A Pilot Open-Label Study. Eu J Neurol. 27(3) (2020) 586-589
  • [12] Daga Ruiz, S.M. Fonseca, F.J. González de Molina, et al. Plasmapheresis and other extracorporeal filtration techniques in critical patients. Med Intensiva 41(3) (2017) 174-187
  • [13] W. Köhler, C. Bucka, R. Klingel, et al. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. Journal of Clinical Apheresis 26(6) (2011) 347-355
  • [14] I. Trikha, S. Singh, V. Goyal, et al. Comparative efficacy of low dose, daily versus alternative day plasma exchange in severe myasthenia gravis: A randomized trial. Journal of Neurology 254 (2007) 989-995
  • [15] M.F. Yazdi, M. Baghianimoghadam, H. Nazmiyeh, et al. Response to plasmapheresis in myasthenia gravis patients: 22 cases report. Rom J Intern Med. 50(3) (2012) 245-247
  • [16] A.J. Pinching, D.K. Peters. Remission of myasthenia gravis following plasma-exchange. Lancet 2 (1976) 1373-1376
  • [17] P.C. Dau, J.M. Lindstrom, C.K. Cassel, et al. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 297(21) (1977) 1134-1140
  • [18] R. Kumar, S.P. Birinder, S. Gupta, et al. Therapeutic plasma exchange in the treatment of myasthenia gravis. Indian J Crit Care Med. 19(1) (2015) 9-13
  • [19] A. Mandawat, A. Mandawat, H.J. Kaminski, et al. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve. 43(4) (2011) 578-84
  • [20] W. Szczeklik, K. Wawrzycka, A. Włudarczyk, Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 45(1) (2013) 7-13.
  • [21] P. Gajdos, S. Chevret, K. Toyka. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 4 (2002) 2275.
  • [22] P.C. Dau. Plasmapheresis in myasthenia gravis. Prog Clin Biol Res. 88 (1982) 265-285.
  • [23] R.L. Rodnitzky, J.A. Goeken. Complications of plasma exchange in neurological patients. Arch Neurol. 39(6) (1982) 350-354
  • [24] H. Ebadi, D. Barth, V. Bril. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve. 47(4) (2013) 510-514
  • [25] A. Alipour-Faz, M. Shojaei, H. Peyvandi. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 117(1) (2017) 245-249.
  • [26] S. Raif. Geha Charles A. Janeway and Fred S. Rosen: The discovery of gamma globulin therapy and primary immunodeficiency diseases at Boston Children's Hospital. Journal of Allergy and Clinical Immunology 116(4) (2005) 937-940
  • [27] J. Rowin. Is plasmapheresis an effective treatment for myasthenia gravis? Americ Academ Of Neurolog. [dostępny 01.06.2019]
  • [28] P. Ortiz-Salas, A. Velez-Van-Meerbeke, C.A. Galvis-Gomez, et al. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis. J Clin Neuromuscul Dis. 18(1) (2016) 1-11
  • [29] G. Barnett, D. Wilson, D. Barth, et al. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 84(1) (2013) 94-97
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.